Page last updated: 2024-12-05

acepromazine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Acepromazine: A phenothiazine that is used in the treatment of PSYCHOSES. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

acepromazine : A member of the class of phenothiazines that is 10H-phenothiazine substituted by an acetyl group at position 2 and a 3-(dimethylamino)propyl group at position 10. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID6077
CHEMBL ID39560
CHEBI ID44932
SCHEMBL ID73018
MeSH IDM0000107

Synonyms (102)

Synonym
ethanone, 1-[10-[3-(dimethylamino)propyl]-10h-phenothiazin-2-yl]-
einecs 200-496-0
1522 cb
promazine, acetyl-
1-(10-(3-(dimethylamino)propyl)-10h-phenothiazin-2-yl)ethanone
ay-57,062
acepromazinum [inn-latin]
acepromazina [inn-spanish]
wy-1172
ketone, 10-(3-(dimethylamino)propyl)phenothiazin-2-yl methyl
acepromazine [inn:ban]
BSPBIO_000392
D07065
acepromazine (inn)
concentrat vo34 (tn)
notensil
plegicil
61-00-7
acepromazine
ethanone, 1-(10-(3-(dimethylamino)propyl)-10h-phenothiazin-2-yl)-
acetylperazine
acetylpromazine
1-[10-[3-(dimethylamino)propyl]phenothiazin-2-yl]ethanone
sv-1522
vetranquil
PRESTWICK3_000576
BPBIO1_000432
1-[10-[3-(dimethylamino)propyl]-10h-phenothiazin-2-yl]-ethanone
2-acetyl-10-(3-dimethylaminopropyl)phenothiazine
10-(3-dimethylaminopropyl)phenothiazin-3-yl methyl ketone
azepromazine
acepromazin
ACE ,
acetyl-promazine
2-acetylpromazine
plivafen
acetazin
acepromazina
1522cb
atsetozin
3-acetyl-10-(3-dimethylaminopropyl)phenothiazine
10-[3-(dimethylamino)propyl]phenothiazin-2-yl methyl ketone
anergan
acetacin
cc64
acetopromazine
1-[10-(3-dimethylamino-propyl)-10h-phenothiazin-2-yl]-ethanone
PMZ ,
10-(3-dimethylaminopropyl)phenothiazine-3-ethylone
CHEBI:44932 ,
1-{10-[3-(dimethylamino)propyl]-10h-phenothiazin-2-yl}ethanone
DB01614
SPBIO_002611
PRESTWICK0_000576
PRESTWICK1_000576
PRESTWICK2_000576
NCGC00016634-02
bdbm50131719
concentrat vo34
acezine 2
atravet
CHEMBL39560 ,
unii-54ej303f0r
ec 200-496-0
54ej303f0r ,
acepromazinum
acepromazine [mart.]
acepromazine [who-dd]
acepromazine [mi]
10-(3-(dimethylamino)propyl)phenothiazin-2-yl methyl ketone
acepromazine [inn]
SCHEMBL73018
2-acetyl-10-[3-(dimethylamino)propyl]phenylthiazine
acetylpromazin
soprontin (salt/mix)
azapromazine
1-(10-[3-(dimethylamino)propyl]-10h-phenothiazin-2-yl)ethanone #
anatran (salt/mix)
soprintin (salt/mix)
acetilpromazina
vetranquill
acepromizina
sedalin (salt/mix)
plegicyl (salt/mix)
ketone, 10-[3-(dimethylamino)propyl]phenothiazin-2-yl methyl
10-[3-(dimethylamino)propyl]-10h-phenothiazin-2-yl methyl ketone
3-acetyl-promazin
10-(3-dimethylaminopropyl)phenothiazine-3-ethanone
1522 c. b.
plivaphen
DTXSID1022552
1-{10-[3-(dimethylamino)propyl]-10h-phenothiazin-2-yl}ethan-1-one
SBI-0206796.P001
Q425097
BRD-K37814297-050-05-4
NCGC00016634-09
61-00-7 (free base)
acepromazina (inn-spanish)
1-(10-(3-dimethylamino-propyl)-10h-phenothiazin-2-yl)-ethanone
acepromazine (mart.)
acepromazinum (inn-latin)
n05aa04

Research Excerpts

Overview

Acepromazine (ACP) is a phenothiazine derivative drug commonly used as a tranquilizer veterinary medication due to its sedative properties. Acepromazine is a useful therapeutic drug, but is a prohibited substance in competition horses.

ExcerptReferenceRelevance
"Acepromazine (ACP) is a phenothiazine derivative drug commonly used as a tranquilizer veterinary medication due to its sedative properties. "( A highly efficient and portable laser-scribed graphene-based electrochemical system for forensic-oriented determination of acepromazine.
de Araujo, WR; de Lima, LF, 2023
)
2.56
"Acepromazine is a tranquilizer used commonly in equine medicine. "( Pharmacokinetics, pharmacodynamics, and metabolism of acepromazine following intravenous, oral, and sublingual administration to exercised Thoroughbred horses.
Kass, PH; Knych, HK; McKemie, DS; Seminoff, K, 2018
)
2.17
"Acepromazine is a phenothiazine derivative used in horses, dogs, and cats."( Acute encephalopathy with concurrent respiratory and metabolic disturbances in first known parenteral human administration of flunixin meglumine and acepromazine maleate.
Acquisto, NM; Kamali, MF; Schneider, SM; Spillane, L; Wilson, AC, 2013
)
1.31
"Acepromazine is a phenothiazine that is used exclusively in veterinary medicine for multiple purposes. "( Acute acepromazine overdose: clinical effects and toxicokinetic evaluation.
Algren, DA; Ashworth, A, 2015
)
2.34
"Acepromazine (ACP) is a useful therapeutic drug, but is a prohibited substance in competition horses. "( Acepromazine pharmacokinetics: a forensic perspective.
Boston, RC; Dunstan, AJ; McKinney, AR; Noble, GK; Schneiders, FI; Sillence, MN, 2012
)
3.26

Effects

IM acepromazine has a modest effect on palmar digital blood flow, facial arterial pressures and PCV in healthy horses with minimal sedation. Ace Promazine has no effect on striated muscle.

ExcerptReferenceRelevance
"IM acepromazine has a modest effect on palmar digital blood flow, facial arterial pressures and PCV in healthy horses with minimal sedation."( Effects of intramuscular administration of acepromazine on palmar digital blood flow, palmar digital arterial pressure, transverse facial arterial pressure, and packed cell volume in clinically healthy, conscious horses.
Eades, SC; Fugler, LA; Leise, BS; Moore, RM; Stokes, AM, 2007
)
1.22
"IM acepromazine has a modest effect on palmar digital blood flow, facial arterial pressures and PCV in healthy horses with minimal sedation."( Effects of intramuscular administration of acepromazine on palmar digital blood flow, palmar digital arterial pressure, transverse facial arterial pressure, and packed cell volume in clinically healthy, conscious horses.
Eades, SC; Fugler, LA; Leise, BS; Moore, RM; Stokes, AM, 2007
)
1.22
"Acepromazine has no effect on striated muscle."( Effects of acepromazine maleate and phenoxybenzamine on urethral pressure profiles of anesthetized, healthy, sexually intact male cats.
Knowlen, GG; Marks, SL; Moore, M; Rishniw, M; Speth, R; Straeter-Knowlen, IM, 1996
)
1.41

Actions

Acepromazine did not increase the count density of the bone phase scintigrams. It did not inhibit 125I-labeled alpha-bungarotoxin binding to nicotinic receptors in skeletal muscle.

ExcerptReferenceRelevance
"Acepromazine did not increase the count density of the bone phase scintigrams."( Effects of acepromazine on three-phase 99mTc-MDP bone imaging in 11 horses.
Johnson, K; Solano, M; Welcome, J,
)
1.24
"Acepromazine did not inhibit 125I-labeled alpha-bungarotoxin binding to nicotinic receptors in murine skeletal muscle."( Effects of acepromazine maleate and phenoxybenzamine on urethral pressure profiles of anesthetized, healthy, sexually intact male cats.
Knowlen, GG; Marks, SL; Moore, M; Rishniw, M; Speth, R; Straeter-Knowlen, IM, 1996
)
1.41

Treatment

ExcerptReferenceRelevance
"In acepromazine-treated cats, 4-AP + yohimbine was the most effective antagonist; arousal and walking occurred in an average of 10.4 minutes and 91.7 minutes, respectively."( Reversal of pentobarbital anesthesia with 4-aminopyridine and yohimbine in cats pretreated with acepromazine and xylazine.
Booth, NH; Clark, JD; Hatch, RC; Kitzman, JV; Zahner, JM, 1984
)
1

Toxicity

ExcerptReferenceRelevance
"The goals of the study were to find a safe intraperitoneal injection anesthesia protocol for medium-duration surgery in mice (e."( Optimization of intraperitoneal injection anesthesia in mice: drugs, dosages, adverse effects, and anesthesia depth.
Arras, M; Autenried, P; Rettich, A; Rülicke, T; Spaeni, D, 2001
)
0.31
" We recommend KXA as a safe and reliable anesthetic for mice requiring a surgical plane of anesthesia."( Safety and efficacy of various combinations of injectable anesthetics in BALB/c mice.
Belicha-Villanueva, A; Buitrago, S; Martin, TE; Tetens-Woodring, J; Wilding, GE, 2008
)
0.35
" Overall, midazolam-ketamine provided safe and effective sedation for catheterization and intubation of both healthy and CI pigs."( Effective and safe anesthesia for Yorkshire and Yucatan swine with and without cardiovascular injury and intervention.
Abusakran-Monday, KA; Burkholder, TH; Foltz, CJ; Linkenhoker, JR; Linton, CG; Rosero, AP; Walden, A, 2010
)
0.36
" A trained and blinded observer documented adverse events from the time hydromorphone was administered until the time dogs were induced for surgery."( Effects of maropitant citrate or acepromazine on the incidence of adverse events associated with hydromorphone premedication in dogs.
Chiavaccini, L; Claude, AK; Dedeaux, A; Hinz, S,
)
0.41

Pharmacokinetics

ExcerptReferenceRelevance
" In dogs, it is used mainly as a preanaesthetic and sedative agent, without the knowledge of pharmacokinetic data in this species."( [The pharmacokinetics and bioavailability of acepromazine in the plasma of dogs].
Hashem, A; Kietzmann, M; Scherkl, R, 1992
)
0.54
"0 mg/kg) and pharmacodynamic interactions of insecticide were studied with centrally acting drugs viz."( Pharmacodynamic interactions of cypermethrin and centrally acting drugs in mice.
Kanwar, RS; Varshneya, C, 1995
)
0.29
" Intravenously administered doses led to a biphasic concentration decay pattern with an alpha-phase distribution half-life of < 3 minutes."( Pharmacokinetics and pharmacodynamics of acepromazine in horses.
Aeschbacher, G; Curry, SH; Marroum, PJ; Webb, AI, 1994
)
0.55
" The mean elimination half-life of propofol was 56."( Pharmacokinetics of propofol infusions, either alone or with ketamine, in sheep premedicated with acepromazine and papaveretum.
Correia, D; Nolan, AM; Reid, J, 1996
)
0.51
" The relatively long half-life of HEPS and its stable behaviour beyond the initial phase make it a valuable indicator of ACP use, and by determining the urine-to-plasma concentration ratios for HEPS, the approximate dose of ACP administration may be estimated."( Acepromazine pharmacokinetics: a forensic perspective.
Boston, RC; Dunstan, AJ; McKinney, AR; Noble, GK; Schneiders, FI; Sillence, MN, 2012
)
1.82
" The metabolite HEPS was modelled separately from the parent ACP as the half-life of the parent was considerably less than that of the metabolite."( A Bayesian approach for estimating detection times in horses: exploring the pharmacokinetics of a urinary acepromazine metabolite.
Boston, R; Dunstan, AJ; McGree, JM; McKinney, AR; Noble, G; Schneiders, F; Sillence, M, 2013
)
0.6

Compound-Compound Interactions

To compare the effects of morphine (MOR), methadone (MET), butorphanol (BUT) and tramadol (TRA) on sedation, cardiorespiratory variables, body temperature and incidence of emesis in dogs.

ExcerptReferenceRelevance
"To evaluate the effects of methadone, administered alone or in combination with acepromazine or xylazine, on sedation and on physiologic values in dogs."( Effects of methadone, alone or in combination with acepromazine or xylazine, on sedation and physiologic values in dogs.
Bettini, CM; Campagnol, D; Choma, JC; Figueroa, CD; Monteiro, ER, 2008
)
0.82
" In all treatments body temperature decreased, this effect being more pronounced in dogs receiving methadone alone or in combination with acepromazine."( Effects of methadone, alone or in combination with acepromazine or xylazine, on sedation and physiologic values in dogs.
Bettini, CM; Campagnol, D; Choma, JC; Figueroa, CD; Monteiro, ER, 2008
)
0.8
" Greater sedation was achieved when methadone was used in combination with acepromazine or xylazine."( Effects of methadone, alone or in combination with acepromazine or xylazine, on sedation and physiologic values in dogs.
Bettini, CM; Campagnol, D; Choma, JC; Figueroa, CD; Monteiro, ER, 2008
)
0.83
"To compare the effects of morphine (MOR), methadone (MET), butorphanol (BUT) and tramadol (TRA), in combination with acepromazine, on sedation, cardiorespiratory variables, body temperature and incidence of emesis in dogs."( Comparative study on the sedative effects of morphine, methadone, butorphanol or tramadol, in combination with acepromazine, in dogs.
Assis, HM; Campagnol, D; Junior, AR; Monteiro, ER; Quitzan, JG, 2009
)
0.77
"  Dogs were allocated randomly to receive 15 μg kg(-1) buprenorphine combined with either 30 μg kg(-1) acepromazine (group 1), 62."( Two doses of dexmedetomidine in combination with buprenorphine for premedication in dogs; a comparison with acepromazine and buprenorphine.
Auckburally, A; Bell, AM; Flaherty, D; Pawson, P; Scott, EM, 2011
)
0.8
"When administered with buprenorphine, at these doses, dexmedetomidine had no advantages in terms of sedation and induction quality over acepromazine."( Two doses of dexmedetomidine in combination with buprenorphine for premedication in dogs; a comparison with acepromazine and buprenorphine.
Auckburally, A; Bell, AM; Flaherty, D; Pawson, P; Scott, EM, 2011
)
0.78
"To investigate the safety, sedative and analgesic properties of methadone in combination with acepromazine prior to neutering in cats."( Methadone in combination with acepromazine as premedication prior to neutering in the cat.
Bortolami, E; Murrell, JC; Slingsby, LS, 2013
)
0.9
"Cats received one of three opioids combined with acepromazine (0."( Methadone in combination with acepromazine as premedication prior to neutering in the cat.
Bortolami, E; Murrell, JC; Slingsby, LS, 2013
)
0.93
"Methadone provided comparable sedation and analgesia to both buprenorphine and butorphanol when combined with acepromazine."( Methadone in combination with acepromazine as premedication prior to neutering in the cat.
Bortolami, E; Murrell, JC; Slingsby, LS, 2013
)
0.89
"Choice of dex or acp, when given with buprenorphine, caused minor, clinically detectable, differences in various characteristics of anaesthesia, but not in the level of analgesia."( Sedative and analgesic effects of buprenorphine, combined with either acepromazine or dexmedetomidine, for premedication prior to elective surgery in cats and dogs.
Grint, NJ; Hunt, JR; Murrell, JC; Taylor, PM, 2013
)
0.62
"Low dose tiletamine-zolazepam combined with methadone provided superior sedation to ACE."( A comparison of low dose tiletamine-zolazepam or acepromazine combined with methadone for pre-anaesthetic medication in cats.
Kloeppel, H; Mair, A; Ticehurst, K, 2014
)
0.66
"To evaluate the antinociceptive effects of intravenous methadone combined with detomidine or acepromazine in adult horses."( Antinociceptive effects of methadone combined with detomidine or acepromazine in horses.
Crosignani, N; Lopes, C; Luna, SP; Pantoja, JC; Puoli, JN; Quarterone, C; Rosa, AC; Taylor, PM, 2016
)
0.89
" Onset latencies and peak-to-peak amplitudes, elicited in the extensor carpi radialis and cranial tibial muscles, were analysed in 10 healthy Beagles that received either acepromazine or dexmedetomidine in combination with levomethadone/fenpipramide, in a crossover design."( Transcranial magnetic stimulation with acepromazine or dexmedetomidine in combination with levomethadone/fenpipramide in healthy Beagle dogs.
Amendt, HL; Kästner, SB; Rohn, K; Schütter, A; Siedenburg, JS; Söbbeler, FJ; Steffensen, N; Stein, VM; Tipold, A; Tünsmeyer, J, 2016
)
0.9
"To evaluate the sedative and cardiopulmonary effects of three methadone doses, combined with acepromazine, in dogs."( Effects of three methadone doses combined with acepromazine on sedation and some cardiopulmonary variables in dogs.
Bitti, FS; Campagnol, D; Loureiro, B; Monteiro, ER; Nunes Junior, JS; Rangel, JP, 2017
)
0.93
" Solutions containing mixtures of methadone combined with acepromazine, medetomidine or xylazine were stored in syringes at 25°C/60%RH."( Chemical stability of morphine and methadone, and of methadone in combination with acepromazine, medetomidine or xylazine, during prolonged storage in syringes.
Lee, DY; Watson, N; Whittem, T, 2017
)
0.92
" When in combination with acepromazine or xylazine, methadone also remained chemically stable, but the combination with medetomidine failed stability criteria prior to 6 months."( Chemical stability of morphine and methadone, and of methadone in combination with acepromazine, medetomidine or xylazine, during prolonged storage in syringes.
Lee, DY; Watson, N; Whittem, T, 2017
)
0.98
"Each dog was treated four times: physiological saline (1 mL) combined with nalbuphine (0."( Comparison of the sedative effects of nalbuphine and butorphanol, alone or in combination with acepromazine in dogs.
Coelho, CM; Gomes, VH; Marques, JL; Oliveira, RL; Silva, MF, 2018
)
0.7
"Butorphanol promoted a higher sedative effect than nalbuphine when alone and combined with acepromazine."( Comparison of the sedative effects of nalbuphine and butorphanol, alone or in combination with acepromazine in dogs.
Coelho, CM; Gomes, VH; Marques, JL; Oliveira, RL; Silva, MF, 2018
)
0.92
"This study evaluated the effects of 3 morphine doses combined with acepromazine, on sedation and physiological parameters in 5 clinically healthy dogs."( Effects of 3 morphine doses, in combination with acepromazine, on sedation and some physiological parameters in dogs.
Campagnol, D; Freire, CD; Monteiro, ER; Nunes, JS; Rabello, TA; Rangel, JPP, 2019
)
1
"To evaluate the sedative and cardiorespiratory effects of IM administration of alfaxalone and butorphanol combined with acepromazine, midazolam, or dexmedetomidine in dogs."( Sedative and cardiorespiratory effects of intramuscular administration of alfaxalone and butorphanol combined with acepromazine, midazolam, or dexmedetomidine in dogs.
Aarnes, TK; Bednarski, RM; Cremer, J; Lerche, P; Murdock, MA; Riccó Pereira, CH, 2020
)
0.98
"4 mg/kg] combined with acepromazine [0."( Sedative and cardiorespiratory effects of intramuscular administration of alfaxalone and butorphanol combined with acepromazine, midazolam, or dexmedetomidine in dogs.
Aarnes, TK; Bednarski, RM; Cremer, J; Lerche, P; Murdock, MA; Riccó Pereira, CH, 2020
)
1.08
"The aim of this study was to compare the effects of methadone combined with detomidine or acepromazine on the quality of sedation and its influence over dissociative anesthesia in healthy horses."( Effect of Methadone Combined With Acepromazine or Detomidine on Sedation and Dissociative Anesthesia in Healthy Horses.
Alonso, BB; Bisetto, SP; Carregaro, AB; Censoni, JB; Reginato, GM; Ueda, GI, 2020
)
1.06
"To evaluate the feasibility of gastroduodenoscopy in dogs premedicated with acepromazine in combination with butorphanol or methadone."( Comparison of the effects of methadone and butorphanol combined with acepromazine for canine gastroduodenoscopy.
Candido, MV; Casoni, D; Lepajoe, J; Salla, KM; Spillmann, T, 2020
)
1.02
"In our study population, the effects of methadone and butorphanol when combined with acepromazine were comparable."( Comparison of the effects of methadone and butorphanol combined with acepromazine for canine gastroduodenoscopy.
Candido, MV; Casoni, D; Lepajoe, J; Salla, KM; Spillmann, T, 2020
)
1.02
"To compare dexmedetomidine with acepromazine for premedication combined with methadone in dogs undergoing brachycephalic obstructive airway syndrome (BOAS) surgery."( Comparison between dexmedetomidine and acepromazine in combination with methadone for premedication in brachycephalic dogs undergoing surgery for brachycephalic obstructive airway syndrome.
Auckburally, A; Flaherty, D; Murison, PJ; Petruccione, I, 2021
)
1.17
"To compare sedative, cardiopulmonary, and adverse effects of 3 nalbuphine doses, administered alone or in combination with acepromazine, in dogs."( Comparison of the sedative effects of three nalbuphine doses, alone or combined with acepromazine, in dogs.
da Silva, MFA; de Cerqueira Teixeira, JG; Gomes, VH; Janiques Borré, LDS; Marques, JLR, 2022
)
1.15
"0 mg/kg, intravenously [IV]) combined with physiologic saline solution (1 mL, IV; treatments SN1."( Comparison of the sedative effects of three nalbuphine doses, alone or combined with acepromazine, in dogs.
da Silva, MFA; de Cerqueira Teixeira, JG; Gomes, VH; Janiques Borré, LDS; Marques, JLR, 2022
)
0.95
"All nalbuphine doses promoted mild sedation when administered alone, and moderate sedation when combined with acepromazine."( Comparison of the sedative effects of three nalbuphine doses, alone or combined with acepromazine, in dogs.
da Silva, MFA; de Cerqueira Teixeira, JG; Gomes, VH; Janiques Borré, LDS; Marques, JLR, 2022
)
1.16

Bioavailability

ExcerptReferenceRelevance
" The bioavailability of the orally administered drug formulation averaged 20%."( [The pharmacokinetics and bioavailability of acepromazine in the plasma of dogs].
Hashem, A; Kietzmann, M; Scherkl, R, 1992
)
0.54
" The bioavailability of the orally administered drug formulation was 55."( Disposition, bioavailability and clinical efficacy of orally administered acepromazine in the horse.
Hashem, A; Keller, H, 1993
)
0.52
" This structure represents a new class of compounds with good bioavailability and low toxicity that bind with high affinity to TAR."( Structure of TAR RNA complexed with a Tat-TAR interaction nanomolar inhibitor that was identified by computational screening.
Du, Z; James, TL; Lind, KE, 2002
)
0.31
" Exploiting the secondary activity of marketed drugs, on the other hand, may help in generating drug leads that can be optimized for the observed side-effect target, while maintaining acceptable bioavailability and toxicity profiles."( Discovery of antiandrogen activity of nonsteroidal scaffolds of marketed drugs.
Abagyan, R; Bisson, WH; Bruey-Sedano, N; Cheltsov, AV; Chen, J; Christopoulos, A; Dalton, JT; Goldberger, N; Lin, B; May, LT; Sexton, PM; Zhang, XK, 2007
)
0.34

Dosage Studied

The median effective dosage (ED50) of propofol for induction of anesthesia was determined in 25 dogs premedicated with acepromazine. The results suggest that transportation is stressful for dogs and that sedation with Acepromazine, at the dosage and timing used, does not affect the intubation process.

ExcerptRelevanceReference
" This TS score was significantly elevated 40 minutes after dosing with ACP, irrespective of whether the horses had been fed or not."( Responses of horses to acepromazine maleate administered orally in a paste.
Kohnke, JR; Martin, IC; Miller, PJ; Rose, RJ, 1987
)
0.58
" The dosage rates of the immobilization combinations for mammmals, birds and reptiles are presented in tabular form."( [Practical advice concerning the immobilization of wild and zoo animals].
von Hegel, G; Wiesner, H, 1985
)
0.27
" The pooled mean dosage level of pentobarbital required for anesthesia was 12."( Meperidine-acepromazine-pentobarbital anesthesia in cats: reversal by 4-aminopyridine and yohimbine.
Booth, NH; Hatch, RC; Zahner, JM, 1984
)
0.66
"Groups of fasted atropinized crossbred dogs of both sexes were injected IM with a standard dosage of a xylazine-acepromazine combination (2."( Acepromazine-xylazine combination in dogs: antagonism with 4-aminopyridine and yohimbine.
Booth, NH; Brown, J; Cronin, MF; Hatch, RC, 1983
)
1.92
" The compound exhibiting the greatest separation between the dosage that reduced rigidity and that which caused sedation was (Z)-2-propionyl-9-[3-(dimethylamino)propylidene]thioxanthene."( Acylthioxanthenes: agents which selectively reduce decerebrate rigidity in the cat.
Ashton, MJ; Chapman, RF; Loveless, AH, 1980
)
0.26
" Effects of two dosage levels of tranquilization on the time and pressure functions are reported."( Physiologic features of the canine esophagus: effects of tranquilization on esophageal motility.
Gaynor, F; Hahn, AW; Hoffer, RE; MacCoy, DM; Moraff, H; Nichols, MF; Rosser, E, 1980
)
0.26
" 3 The dosage range for Azp was adequate for reduction of individual movement and inter-animal distance but steady state effect was not reached in the time period studied."( Effects of azaperone and acetylpromazine on social and environmental behaviour in sheep.
Madsen, BW; Syme, GJ; Syme, LA, 1980
)
0.26
" Although adverse sequelae to these episodes of hypertension were not noticed, this report documents the uptake of phenylephrine from topical ocular application and suggests the need for dose-response measurements for this adjunct to mydriatic treatment in dogs."( Arterial hypertension associated with topical ocular use of phenylephrine in dogs.
Ilkiw, JE; Pascoe, PJ; Smith, EM; Stiles, J, 1994
)
0.29
"We tested the hypothesis that a single systemic injection of 380 mg/kg of the muscarinic agonist pilocarpine would produce more diffuse and severe seizure-induced brain damage than a single injection of lithium (3 mEq/kg) followed 4 h later by < 1/10 the dosage of pilocarpine."( Concordance of quantitative damage within the diencephalon and telencephalon following systemic pilocarpine (380 mg/kg) or lithium (3 mEq/kg)/pilocarpine (30 mg/kg) induced seizures.
Bureau, YR; Peredery, O; Persinger, MA, 1994
)
0.29
"The cardiorespiratory effects of thiamylal (10 mg/kg of body weight, IV) and the effects of preanesthetic medication with diazepam, acepromazine, detomidine, or xylazine administered prior to a thiamylal dosage of 6 mg/kg, IV, were evaluated in 6 adult horses."( Effects of diazepam, acepromazine, detomidine, and xylazine on thiamylal anesthesia in horses.
Mason, DE; Muir, WW, 1993
)
0.81
" There were wide variations in the blood propofol concentrations reached in individual sheep by using this standard dosing regimen."( Pharmacokinetics of propofol infusions, either alone or with ketamine, in sheep premedicated with acepromazine and papaveretum.
Correia, D; Nolan, AM; Reid, J, 1996
)
0.51
" These results suggest that transportation is stressful for dogs and that sedation with acepromazine, at the dosage and timing used, does not affect the physiological and behavioral stress responses of dogs to air transport."( Physiology and behavior of dogs during air transport.
Bergeron, R; Cook, NJ; Emond, JP; Mercier, F; Schaefer, AL; Scott, SL, 2002
)
0.54
" Recommendation on dosage are given."( Experience with drugs for capture and restraint of wildebeest, impala, eland and hartebeest in Kenya.
Drevemo, SA; Grootenhuis, JG; Karstad, L, 1976
)
0.26
"5, 1, 2, 4, 8, 12 and 24 hours after drug dosing in a separate occasion."( Contact heat thermal threshold testing in beagle dogs: baseline reproducibility and the effect of acepromazine, levomethadone and fenpipramide.
Hoffmann, MV; Kästner, SB; Kietzmann, M; Kramer, S, 2012
)
0.6
" Detomidine induced sedation and antinociception, but only antinociception was dosage dependent."( Sedation and mechanical antinociception after intravenous administration of detomidine in donkeys: a dosage-effect study.
Castillo-Alcala, F; Lizarraga, I; Robinson, LS; Varner, KM, 2015
)
0.42
"To determine the effects of intravenous (IV) premedication with acepromazine, butorphanol or their combination, on the propofol anesthetic induction dosage in dogs."( Effects of intravenous acepromazine and butorphanol on propofol dosage for induction of anesthesia in healthy Beagle dogs.
Dantino, SC; Kleine, SA; Seddighi, R; Smith, CK; Smith, SM; Zhu, X, 2022
)
1.27
"Although the largest decrease in propofol dosage required for intubation was after IV premedication with acepromazine and butorphanol, hypotension and apnea still occurred."( Effects of intravenous acepromazine and butorphanol on propofol dosage for induction of anesthesia in healthy Beagle dogs.
Dantino, SC; Kleine, SA; Seddighi, R; Smith, CK; Smith, SM; Zhu, X, 2022
)
1.25
" The consistency of respiratory parameters during the entire exposure time is paramount to ensuring dosing accuracy."( Comparison of Alfaxalone-Midazolam, Tiletamine-Zolazepam, and KetamineAcepromazine Anesthesia during Plethysmography in Cynomolgus Macaques (
Astleford, SM; Bowling, PA; Casselman, AM; Dixon, BC; Ghering, JM; Marion, BM; White, CE, 2022
)
0.96
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
phenothiazine antipsychotic drugnull
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (4)

ClassDescription
phenothiazines
methyl ketoneA ketone of formula RC(=O)CH3 (R =/= H).
aromatic ketoneA ketone in which the carbonyl group is attached to an aromatic ring.
tertiary amino compoundA compound formally derived from ammonia by replacing three hydrogen atoms by organyl groups.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (8)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
thyroid stimulating hormone receptorHomo sapiens (human)Potency7.94330.001318.074339.8107AID926; AID938
cytochrome P450 2D6 isoform 1Homo sapiens (human)Potency2.51190.00207.533739.8107AID891
gemininHomo sapiens (human)Potency8.05240.004611.374133.4983AID624297
lethal factor (plasmid)Bacillus anthracis str. A2012Potency2.51190.020010.786931.6228AID912
lamin isoform A-delta10Homo sapiens (human)Potency5.62340.891312.067628.1838AID1487
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Bile salt export pumpHomo sapiens (human)IC50 (µMol)111.60000.11007.190310.0000AID1449628
Trypanothione reductaseTrypanosoma cruziIC50 (µMol)502.00005.80005.80005.8000AID214488
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Major prion proteinHomo sapiens (human)EC50 (µMol)5.00000.30004.900010.0000AID161627
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (59)

Processvia Protein(s)Taxonomy
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
cellular response to copper ionMajor prion proteinHomo sapiens (human)
negative regulation of protein phosphorylationMajor prion proteinHomo sapiens (human)
intracellular copper ion homeostasisMajor prion proteinHomo sapiens (human)
response to oxidative stressMajor prion proteinHomo sapiens (human)
learning or memoryMajor prion proteinHomo sapiens (human)
long-term memoryMajor prion proteinHomo sapiens (human)
negative regulation of protein processingMajor prion proteinHomo sapiens (human)
protein destabilizationMajor prion proteinHomo sapiens (human)
negative regulation of type II interferon productionMajor prion proteinHomo sapiens (human)
negative regulation of interleukin-17 productionMajor prion proteinHomo sapiens (human)
negative regulation of interleukin-2 productionMajor prion proteinHomo sapiens (human)
negative regulation of apoptotic processMajor prion proteinHomo sapiens (human)
negative regulation of DNA-binding transcription factor activityMajor prion proteinHomo sapiens (human)
positive regulation of neuron apoptotic processMajor prion proteinHomo sapiens (human)
negative regulation of activated T cell proliferationMajor prion proteinHomo sapiens (human)
response to cadmium ionMajor prion proteinHomo sapiens (human)
regulation of peptidyl-tyrosine phosphorylationMajor prion proteinHomo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationMajor prion proteinHomo sapiens (human)
positive regulation of calcium-mediated signalingMajor prion proteinHomo sapiens (human)
negative regulation of T cell receptor signaling pathwayMajor prion proteinHomo sapiens (human)
protein homooligomerizationMajor prion proteinHomo sapiens (human)
regulation of cell cycleMajor prion proteinHomo sapiens (human)
negative regulation of calcineurin-NFAT signaling cascadeMajor prion proteinHomo sapiens (human)
cellular response to xenobiotic stimulusMajor prion proteinHomo sapiens (human)
positive regulation of protein targeting to membraneMajor prion proteinHomo sapiens (human)
dendritic spine maintenanceMajor prion proteinHomo sapiens (human)
negative regulation of long-term synaptic potentiationMajor prion proteinHomo sapiens (human)
regulation of glutamate receptor signaling pathwayMajor prion proteinHomo sapiens (human)
positive regulation of glutamate receptor signaling pathwayMajor prion proteinHomo sapiens (human)
regulation of potassium ion transmembrane transportMajor prion proteinHomo sapiens (human)
negative regulation of amyloid-beta formationMajor prion proteinHomo sapiens (human)
negative regulation of dendritic spine maintenanceMajor prion proteinHomo sapiens (human)
negative regulation of amyloid precursor protein catabolic processMajor prion proteinHomo sapiens (human)
positive regulation of protein localization to plasma membraneMajor prion proteinHomo sapiens (human)
response to amyloid-betaMajor prion proteinHomo sapiens (human)
cellular response to amyloid-betaMajor prion proteinHomo sapiens (human)
regulation of calcium ion import across plasma membraneMajor prion proteinHomo sapiens (human)
neuron projection maintenanceMajor prion proteinHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (29)

Processvia Protein(s)Taxonomy
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
type 8 metabotropic glutamate receptor bindingMajor prion proteinHomo sapiens (human)
amyloid-beta bindingMajor prion proteinHomo sapiens (human)
protease bindingMajor prion proteinHomo sapiens (human)
copper ion bindingMajor prion proteinHomo sapiens (human)
protein bindingMajor prion proteinHomo sapiens (human)
lamin bindingMajor prion proteinHomo sapiens (human)
glycosaminoglycan bindingMajor prion proteinHomo sapiens (human)
microtubule bindingMajor prion proteinHomo sapiens (human)
tubulin bindingMajor prion proteinHomo sapiens (human)
aspartic-type endopeptidase inhibitor activityMajor prion proteinHomo sapiens (human)
type 5 metabotropic glutamate receptor bindingMajor prion proteinHomo sapiens (human)
signaling receptor activityMajor prion proteinHomo sapiens (human)
identical protein bindingMajor prion proteinHomo sapiens (human)
ATP-dependent protein bindingMajor prion proteinHomo sapiens (human)
transmembrane transporter bindingMajor prion proteinHomo sapiens (human)
protein-containing complex bindingMajor prion proteinHomo sapiens (human)
protein-folding chaperone bindingMajor prion proteinHomo sapiens (human)
molecular adaptor activityMajor prion proteinHomo sapiens (human)
molecular function activator activityMajor prion proteinHomo sapiens (human)
molecular condensate scaffold activityMajor prion proteinHomo sapiens (human)
cupric ion bindingMajor prion proteinHomo sapiens (human)
cuprous ion bindingMajor prion proteinHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (26)

Processvia Protein(s)Taxonomy
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
dendriteMajor prion proteinHomo sapiens (human)
cytoplasmMajor prion proteinHomo sapiens (human)
endoplasmic reticulumMajor prion proteinHomo sapiens (human)
Golgi apparatusMajor prion proteinHomo sapiens (human)
cytosolMajor prion proteinHomo sapiens (human)
plasma membraneMajor prion proteinHomo sapiens (human)
external side of plasma membraneMajor prion proteinHomo sapiens (human)
cell surfaceMajor prion proteinHomo sapiens (human)
postsynaptic densityMajor prion proteinHomo sapiens (human)
inclusion bodyMajor prion proteinHomo sapiens (human)
extrinsic component of membraneMajor prion proteinHomo sapiens (human)
nuclear membraneMajor prion proteinHomo sapiens (human)
terminal boutonMajor prion proteinHomo sapiens (human)
intracellular membrane-bounded organelleMajor prion proteinHomo sapiens (human)
membrane raftMajor prion proteinHomo sapiens (human)
extracellular exosomeMajor prion proteinHomo sapiens (human)
postsynapseMajor prion proteinHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (42)

Assay IDTitleYearJournalArticle
AID327647Inhibition of wild type androgen receptor expressed in CV1 cells assessed as dihydrotestosterone-stimulated transactivation at 500 nM by CAT reporter gene assay2007Proceedings of the National Academy of Sciences of the United States of America, Jul-17, Volume: 104, Issue:29
Discovery of antiandrogen activity of nonsteroidal scaffolds of marketed drugs.
AID1057862Inhibition of RML prion protein infected in mouse dividing ScN2a-cl3 cells expressing full length mouse PrP assessed as reduction of PrPsc level after 5 days by ELISA2013Bioorganic & medicinal chemistry, Dec-15, Volume: 21, Issue:24
Antiprion compounds that reduce PrP(Sc) levels in dividing and stationary-phase cells.
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID250135Inhibition of compound against MES-SA/DX5 cell line was determined using P-glycoprotein assay2005Journal of medicinal chemistry, Apr-21, Volume: 48, Issue:8
A pharmacophore hypothesis for P-glycoprotein substrate recognition using GRIND-based 3D-QSAR.
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID113845Effective dose against Leishmania donovani (Leishmania donovani) amastigotes in mouse peritoneal macrophages; Toxic to the macrophages1998Journal of medicinal chemistry, Jan-15, Volume: 41, Issue:2
Phenothiazine inhibitors of trypanothione reductase as potential antitrypanosomal and antileishmanial drugs.
AID135601Reduction of locomotor activity count to 50% of the control in mouse after oral administration1980Journal of medicinal chemistry, Jun, Volume: 23, Issue:6
Acylthioxanthenes: agents which selectively reduce decerebrate rigidity in the cat.
AID113853Effective dose against Trypanosoma cruzi (Trypanosoma cruzi) trypomastigotes in mouse peritoneal macrophages; Toxic to the macrophages1998Journal of medicinal chemistry, Jan-15, Volume: 41, Issue:2
Phenothiazine inhibitors of trypanothione reductase as potential antitrypanosomal and antileishmanial drugs.
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID214488Inhibitory activity against recombinant Trypanosoma cruzi (Trypanosoma cruzi) Trypanothione reductase1998Journal of medicinal chemistry, Jan-15, Volume: 41, Issue:2
Phenothiazine inhibitors of trypanothione reductase as potential antitrypanosomal and antileishmanial drugs.
AID113847Effective dose against Trypanosoma brucei) trypomastigotes in mouse peritoneal macrophages1998Journal of medicinal chemistry, Jan-15, Volume: 41, Issue:2
Phenothiazine inhibitors of trypanothione reductase as potential antitrypanosomal and antileishmanial drugs.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID1057863Cytotoxicity against mouse dividing ScN2a-cl3 cells assessed as cell viability after 5 days by calcein-AM staining-based fluorescence assay2013Bioorganic & medicinal chemistry, Dec-15, Volume: 21, Issue:24
Antiprion compounds that reduce PrP(Sc) levels in dividing and stationary-phase cells.
AID161627Half maximal inhibition of Prion protein PrPsc formation was assayed in ScN2a cells2003Journal of medicinal chemistry, Aug-14, Volume: 46, Issue:17
Antimalarial drug quinacrine binds to C-terminal helix of cellular prion protein.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID229838Ratio of motor activity and activity A1980Journal of medicinal chemistry, Jun, Volume: 23, Issue:6
Acylthioxanthenes: agents which selectively reduce decerebrate rigidity in the cat.
AID49904Reduction of the integrated electromyographic response by 50% in cat after peroral administration1980Journal of medicinal chemistry, Jun, Volume: 23, Issue:6
Acylthioxanthenes: agents which selectively reduce decerebrate rigidity in the cat.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID238114Dissociation constant of the compound2004Journal of medicinal chemistry, Aug-12, Volume: 47, Issue:17
Validation of automated docking programs for docking and database screening against RNA drug targets.
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID1057864Ratio of LC50 for dividing mouse ScN2a-cl3 cells to EC50 for inhibition of RML prion protein2013Bioorganic & medicinal chemistry, Dec-15, Volume: 21, Issue:24
Antiprion compounds that reduce PrP(Sc) levels in dividing and stationary-phase cells.
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID1449628Inhibition of human BSEP expressed in baculovirus transfected fall armyworm Sf21 cell membranes vesicles assessed as reduction in ATP-dependent [3H]-taurocholate transport into vesicles incubated for 5 mins by Topcount based rapid filtration method2012Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID49902Reduction of the integrated electromyographic response by 50% in cat after intravenous administration1980Journal of medicinal chemistry, Jun, Volume: 23, Issue:6
Acylthioxanthenes: agents which selectively reduce decerebrate rigidity in the cat.
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1508627Counterscreen qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: GLuc-NoTag assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1508629Cell Viability qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1508628Confirmatory qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (692)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990272 (39.31)18.7374
1990's104 (15.03)18.2507
2000's132 (19.08)29.6817
2010's145 (20.95)24.3611
2020's39 (5.64)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 54.53

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index54.53 (24.57)
Research Supply Index6.77 (2.92)
Research Growth Index4.52 (4.65)
Search Engine Demand Index151.13 (26.88)
Search Engine Supply Index3.27 (0.95)

This Compound (54.53)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials137 (18.59%)5.53%
Reviews9 (1.22%)6.00%
Case Studies34 (4.61%)4.05%
Observational1 (0.14%)0.25%
Other556 (75.44%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]